AbbVie Inc
4AB.XETRA
| Exchange: | XETRA |
| Currency | Euro |
| ISIN: | US00287Y1091 |
| LEI: | FR5LCKFTG8054YNNRU85 |
| Primary Ticker: | ABBV.US |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Description: | Abb Vie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Address: | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 |
| Website: | https://www.abbvie.com |
| Full Time Employees: | 50000 |
| Updated On: | 2024-11-04 |
Highlights
| Market Capitalization: | 330588192768 |
| Market Capitalization Mln: | 330588.19 |
| EBITDA: | 27156000768 |
| PE Ratio: | 71.16 |
| PEG Ratio: | 0.47 |
| Book Value: | 3.83 |
| Dividend Share: | 6.2 |
| Dividend Yield: | 0.03 |
| Earnings Share: | 2.63 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.09 |
| Operating Margin TTM: | 0.33 |
| Return On Assets TTM: | 0.07 |
| Return On Equity TTM: | 0.54 |
| Revenue TTM: | 55532998656 |
| Revenue Per Share TTM: | 31.41 |
| Quarterly Revenue Growth YOY: | 0.03 |
| Gross Profit TTM: | 41527000000 |
| Diluted Eps TTM: | 2.63 |
| Quarterly Earnings Growth YOY: | -0.1 |
Valuation
| Trailing PE: | 71.16 |
| Forward PE: | 17.06 |
| Price Sales TTM: | 5.98 |
| Price Book MRQ: | 53.35 |
| Enterprise Value: | 390108577792 |
| Enterprise Value Revenue: | 7.50 |
| Enterprise Value Ebitda: | 44.78 |
Shares
| Shares Outstanding: | 1766339968 |
| Shares Float: | 1763199653 |
| Percent Insiders: | 0.09 |
| Percent Institutions: | 73.47 |
Technicals
| Beta: | 0.61 |
| 52 Week High: | 190.12 |
| 52 Week Low: | 120.68 |
| 50 Day MA: | 176.36 |
| 200 Day MA: | 163.77 |
Splits & Dividends
| Forward Annual Dividend Rate: | 6.06 |
| Forward Annual Dividend Yield: | 0.03 |
| Payout Ratio: | 0.03 |
| Ex Dividend Date: | 2025-01-15 |
Earnings
| Report Date: | 2025-07-23 |
| Date: | 2025-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-04-24 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2025-01-31 |
| Date: | 2024-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2024-10-30 |
| Date: | 2024-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Report Date: | 2024-07-25 |
| Date: | 2024-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.71 |
| Report Date: | 2024-04-26 |
| Date: | 2024-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.71 |
| Report Date: | 2024-03-14 |
| Date: | 2023-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.43 |
| Report Date: | 2023-10-27 |
| Date: | 2023-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.92 |
| Report Date: | 2023-07-27 |
| Date: | 2023-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 1.05 |
| Report Date: | 2023-04-27 |
| Date: | 2023-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.12 |
| Report Date: | 2023-02-09 |
| Date: | 2022-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 1.36 |
| Report Date: | 2022-10-28 |
| Date: | 2022-09-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 2.20 |
| Report Date: | 2022-07-29 |
| Date: | 2022-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 0.48 |
| Report Date: | 2022-04-29 |
| Date: | 2022-03-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | 2.25 |
| Report Date: | 2022-02-02 |
| Date: | 2021-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | 1.98 |
| Report Date: | 2021-10-29 |
| Date: | 2021-09-30 |
| Currency: | EUR |
| Eps Actual: | 1.51 |
| Report Date: | 2021-07-30 |
| Date: | 2021-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.34 |
| Report Date: | 2021-04-30 |
| Date: | 2021-03-31 |
| Currency: | EUR |
| Eps Actual: | 1.66 |
| Report Date: | 2021-02-03 |
| Date: | 2020-12-31 |
| Currency: | EUR |
| Report Date: | 2020-09-30 |
| Date: | 2020-09-30 |
| Currency: | EUR |
| Eps Actual: | 1.10 |
| Report Date: | 2020-06-30 |
| Date: | 2020-06-30 |
| Currency: | EUR |
| Eps Actual: | -0.41 |
| Report Date: | 2020-03-31 |
| Date: | 2020-03-31 |
| Currency: | EUR |
| Eps Actual: | 1.83 |
| Report Date: | 2019-12-31 |
| Date: | 2019-12-31 |
| Currency: | EUR |
| Eps Actual: | 1.69 |
| Report Date: | 2019-09-30 |
| Date: | 2019-09-30 |
| Currency: | EUR |
| Eps Actual: | 1.13 |
| Report Date: | 2019-06-30 |
| Date: | 2019-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.43 |
| Report Date: | 2019-03-31 |
| Date: | 2019-03-31 |
| Currency: | EUR |
| Eps Actual: | 1.45 |
| Report Date: | 2018-12-31 |
| Date: | 2018-12-31 |
| Currency: | EUR |
| Eps Actual: | -1.07 |
| Report Date: | 2018-09-30 |
| Date: | 2018-09-30 |
| Currency: | EUR |
| Eps Actual: | 1.55 |
| Report Date: | 2018-06-30 |
| Date: | 2018-06-30 |
| Currency: | EUR |
| Eps Actual: | 1.05 |
| Report Date: | 2018-03-31 |
| Date: | 2018-03-31 |
| Currency: | EUR |
| Eps Actual: | 1.41 |
| Report Date: | 2017-12-31 |
| Date: | 2017-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.02 |
| Report Date: | 2017-09-30 |
| Date: | 2017-09-30 |
| Currency: | EUR |
| Eps Actual: | 0.86 |
| Report Date: | 2017-06-30 |
| Date: | 2017-06-30 |
| Currency: | EUR |
| Eps Actual: | 1.08 |
| Report Date: | 2017-03-31 |
| Date: | 2017-03-31 |
| Currency: | EUR |
| Eps Actual: | 0.99 |
| Report Date: | 2016-12-31 |
| Date: | 2016-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.79 |
| Report Date: | 2016-09-30 |
| Date: | 2016-09-30 |
| Currency: | EUR |
| Eps Actual: | 0.86 |
| Report Date: | 2016-06-30 |
| Date: | 2016-06-30 |
| Currency: | EUR |
| Eps Actual: | 0.86 |
| Report Date: | 2016-03-31 |
| Date: | 2016-03-31 |
| Currency: | EUR |
| Eps Actual: | 0.75 |
| Report Date: | 2015-12-31 |
| Date: | 2015-12-31 |
| Currency: | EUR |
| Eps Actual: | 0.84 |
| Date: | 2024-09-30 |
| Eps Actual: | 1.4 |
| Date: | 2023-12-31 |
| Eps Actual: | 2.52 |
| Date: | 2022-12-31 |
| Eps Actual: | 6.31 |
| Date: | 2021-12-31 |
| Eps Actual: | 5.51 |
| Date: | 2020-12-31 |
| Eps Actual: | 2.53 |
| Date: | 2019-12-31 |
| Eps Actual: | 4.72 |
| Date: | 2018-12-31 |
| Eps Actual: | 2.94 |
| Date: | 2017-12-31 |
| Eps Actual: | 2.96 |
| Date: | 2016-12-31 |
| Eps Actual: | 3.28 |
| Date: | 2015-12-31 |
| Eps Actual: | 0.84 |